Pustular Psoriasis Clinical Trials

Find Pustular Psoriasis Clinical Trials Near You

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis

Status: Recruiting
Location: See all (32) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Age ≥ 18 or ≤75 years old at screening, regardless of gender;

• Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as (generalized pustular psoriasis(GPP);

• Compliant with GPP acute onset;

• Able to read and understand, and willing to sign the informed consent form;

• Willing and compliant with study visits and related procedures;

• Female subjects of childbearing age should agree that contraceptive measures must be used during the study and for 6 months after the end of the study;

Locations
Other Locations
China
Peking University First Hospita
RECRUITING
Beijing
Peking University Third Hospital
NOT_YET_RECRUITING
Beijing
The first hospital of jilin university
NOT_YET_RECRUITING
Changchun
The First Hospital of Hunan University of Chinese Medicine
NOT_YET_RECRUITING
Changsha
Xiangya Hospital of Central South University
NOT_YET_RECRUITING
Changsha
Chengdu Second People's Hospital
NOT_YET_RECRUITING
Chengdu
Sichuan Provincial People' s Hospital
NOT_YET_RECRUITING
Chengdu
The First Affiliated Hospital of Fujian Medical University
NOT_YET_RECRUITING
Fuzhou
Southern Medical University Dermatology Hospital
NOT_YET_RECRUITING
Guangzhou
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
NOT_YET_RECRUITING
Guangzhou
The Affiliated Hospital of Guizhou Medical University
NOT_YET_RECRUITING
Guiyang
The General Hospital Of Hunan University Of Medicine
NOT_YET_RECRUITING
Huaihua
Jiaxing First Hospital
NOT_YET_RECRUITING
Jiaxing
Shandong First Medical University Affiliated Dermatology Hospital
NOT_YET_RECRUITING
Jinan
The First Affiliated Hospital of Kunming Medical University
NOT_YET_RECRUITING
Kunming
The Second Affiliated Hospital of Henan University of science and technology
NOT_YET_RECRUITING
Luoyang
The Affiliated Hospital of Southwest Medical University
NOT_YET_RECRUITING
Luzhou
The Affiliated Hospital of Southwest Medical University
NOT_YET_RECRUITING
Luzhou
The first affiliated hospital of ningbo university
NOT_YET_RECRUITING
Ningbo
Shanghai Skin Disease Hospital
NOT_YET_RECRUITING
Shanghai
The first hospital of china medical university
NOT_YET_RECRUITING
Shenyang
The Second Hospital Of Hebei Medical University
NOT_YET_RECRUITING
Shijiazhuang
Shiyan Renmin Hospital
NOT_YET_RECRUITING
Shiyan
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
NOT_YET_RECRUITING
Tianjin
Tianjin Medical University General Hospital
NOT_YET_RECRUITING
Tianjin
People's Hospital of Xinjiang Uygur Autonomous Region
NOT_YET_RECRUITING
Ürümqi
The First Affiliated Hospital of Xinjiang Medical University
NOT_YET_RECRUITING
Ürümqi
Renmin Hospital of Wuhan University
NOT_YET_RECRUITING
Wuhan
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITING
Xi’an
Henan Provincial People's Hospital
NOT_YET_RECRUITING
Zhengzhou
The fifth Affiliated hospital of zhengzhou university
NOT_YET_RECRUITING
Zhengzhou
Zhengzhou Central Hospital
NOT_YET_RECRUITING
Zhengzhou
Contact Information
Primary
Hang Li, Doctor
drlihang@126.com
13693058190
Time Frame
Start Date: 2026-03-19
Estimated Completion Date: 2027-07
Participants
Target number of participants: 36
Treatments
Experimental: TQH2929 Injections
Intravenous infusion, single dose
Placebo_comparator: TQH2929 Placebo
Intravenous infusion, single dose
Sponsors
Leads: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This content was sourced from clinicaltrials.gov